IMBCR is dedicated to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care.
Daratumumab Decreased Progression Risk in High-Risk Smoldering MM
Risk Factors Determine Symptom Burden Profiles by Age Group
Study Findings Support D-VRd for Transplant-Ineligible or -Deferred MM
Real-World Data Shows Apalutamide Increases 24-Month OS in mCSPC